Phreesia (NYSE:PHR) Price Target Raised to $34.00 at JMP Securities

Phreesia (NYSE:PHR) had its price objective boosted by JMP Securities from $30.00 to $34.00 in a research note issued to investors on Monday, Marketbeat Ratings reports. They currently have a market outperform rating on the stock.

A number of other equities analysts also recently weighed in on PHR. Raymond James Financial set a $33.00 price target on Phreesia and gave the stock an “outperform” rating in a research report on Friday, September 5th. Citigroup reissued a “buy” rating on shares of Phreesia in a research report on Wednesday, May 28th. Canaccord Genuity Group boosted their price target on Phreesia from $34.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, September 5th. KeyCorp boosted their price target on Phreesia from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Monday, July 14th. Finally, Stephens reissued an “overweight” rating and set a $32.00 price target on shares of Phreesia in a research report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the stock. According to MarketBeat, Phreesia currently has an average rating of “Buy” and an average target price of $34.08.

Phreesia Price Performance

NYSE:PHR opened at $25.34 on Monday. The stock’s 50-day simple moving average is $28.19 and its 200 day simple moving average is $26.50. The company has a market cap of $1.52 billion, a P/E ratio of -60.33 and a beta of 0.72. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 2.12. Phreesia has a 52-week low of $17.07 and a 52-week high of $32.76.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.08. The firm had revenue of $117.26 million for the quarter, compared to the consensus estimate of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The business’s revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.03) earnings per share. Phreesia has set its FY 2026 guidance at EPS. As a group, sell-side analysts forecast that Phreesia will post -1.1 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Evan Roberts sold 45,147 shares of the company’s stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $32.02, for a total value of $1,445,606.94. Following the transaction, the insider owned 727,768 shares of the company’s stock, valued at approximately $23,303,131.36. This represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark Douglas Smith sold 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $29.00, for a total value of $203,000.00. Following the completion of the transaction, the director directly owned 37,353 shares in the company, valued at $1,083,237. The trade was a 15.78% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,292 shares of company stock valued at $3,295,323 in the last ninety days. 5.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Phreesia

A number of large investors have recently added to or reduced their stakes in PHR. KBC Group NV bought a new stake in Phreesia during the first quarter worth $74,000. Farther Finance Advisors LLC lifted its stake in shares of Phreesia by 9,375.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock valued at $86,000 after acquiring an additional 3,000 shares during the last quarter. CWM LLC lifted its stake in shares of Phreesia by 994.9% in the 1st quarter. CWM LLC now owns 4,040 shares of the company’s stock valued at $103,000 after acquiring an additional 3,671 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Phreesia by 53.0% in the 1st quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company’s stock valued at $137,000 after acquiring an additional 1,825 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Phreesia by 332.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,610 shares of the company’s stock worth $160,000 after purchasing an additional 4,313 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.